Cardiomyopathy caused by antineoplastic therapies

  • Valeriano C. SimbreII
  • M. Jacob Adams
  • Sampada S. Deshpande
  • Sarah A. Duffy
  • Tracie L. Miller
  • Steven E. Lipshultz
Article

Opinion statement

The goals of care for patients at risk for cardiomyopathy induced by cancer treatment should include prevention, early diagnosis, treatment of subclinical cardiac dysfunction, prevention of disease progression, and prolongation of patient survival. Any strategy aimed to minimize the cardiotoxic effects of cancer treatment should maintain the treatment’s antineoplastic efficacy. Successful therapy achieves the highest health-related quality of life that is defined by the balance between maximizing the efficacy of oncologic therapy and minimizing the toxicity of this therapy. Doxorubicin-induced cardiotoxicity can be reduced by limiting the overall cumulative dose.

There is no specific treatment for cancer therapy-related cardiomyopathy, and symptomatic patients should receive standard treatments for congestive heart failure such as afterload reduction, beta-blockers, diuresis, and digoxin. Afterload reduction with angiotensin-converting enzyme inhibitors such as enalapril and captopril may be indicated in patients with elevated afterload and asymptomatic left ventricular dysfunction diagnosed by echocardiography. Beta-blockers may improve myocardial systolic dysfunction and may be useful in the treatment of cancer treatment-induced cardiomyopathy.

Cardiac transplantation remains a viable option in patients with cancer treatment-induced end-stage heart disease.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Frishman WH, Sung HM, Yee HCM, et al.: Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cardiol 1996, 21:225–286.PubMedGoogle Scholar
  2. 2.
    Stone RM, Bridges KR, Libby P: Hematological-oncological disorders and cardiovascular disease. In Heart Disease, edn 6. Edited by Braunwald E, Zipes DP, Libby P, et al. Philadelphia: WB Saunders Co; 2001:2223–2243.Google Scholar
  3. 3.
    Giantris A, Abdurrahman L, Hinkle A, et al.: Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998, 27:53–68. A comprehensive review of anthracycline cardiotoxicity.PubMedGoogle Scholar
  4. 4.
    Von Hoff DD, Layard MW, Basa P, et al.: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710–717.Google Scholar
  5. 5.
    Lipshultz SE, Colan SD, Gelber RD, et al.: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991, 324:808–815.PubMedCrossRefGoogle Scholar
  6. 6.
    Liphshultz SE, Lipsitz S, Goorin AM, et al.: Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995, 332:1738–1743.CrossRefGoogle Scholar
  7. 7.
    Krischer JP, Epstein S, Cuthbertson DD, et al.: Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the pediatric oncology group experience. J Clin Oncol 1997, 15:1544–1552.PubMedGoogle Scholar
  8. 8.
    Nysom K, Holm K, Lipsitz SR, et al.: The relation between cumulative anthracylcine dose and late cardiotoxicity in survivors of childhood leukemia. J Clin Oncol 1998, 16:545–550.PubMedGoogle Scholar
  9. 9.
    Grenier MA, Lipshultz SE: Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998, 25(suppl 10):72–85.PubMedGoogle Scholar
  10. 10.
    Lipshultz SE, Sanders SP, Goorin A, et al.: Monitoring for anthracycline cardiotoxicity. Pediatrics 1994 93:433–437.PubMedGoogle Scholar
  11. 11.
    Ensley JF, Patel B, Kloner R, et al.: The clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs 1989, 7:101–109.PubMedCrossRefGoogle Scholar
  12. 12.
    Willemze R, Zwaan FE, Colpin G, et al.: High dose cytosine arabinoside in the management of refractory acute leukaemia. Scand J Haematol 1982, 29:141–146.PubMedCrossRefGoogle Scholar
  13. 13.
    Vaickus L, Letendre L: Pericarditis induced by highdose cytarabine therapy. Arch Intern Med 1984, 144:1868–1869.PubMedCrossRefGoogle Scholar
  14. 14.
    Rowinsky EK, Gilbert MR, McGuire WP, et al.: Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991, 9:1692–1703.PubMedGoogle Scholar
  15. 15.
    Rowinsky EK, McGuire WP, Guarnieri T, et al.: Cardiac disturbances during the administration of taxol. J Clin Oncol 1991, 9:1704–1712.PubMedGoogle Scholar
  16. 16.
    Arbuck SG, Strauss H, Rowinsky E, et al.: A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 1993, 15:117–30.PubMedGoogle Scholar
  17. 17.
    Feldman AM, Lorell BH, Reis SE: Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 2000, 102:272–274. Important review of potential mechanisms of trastuzumab cardiotoxicity.PubMedGoogle Scholar
  18. 18.
    Adams MJ, Constine LS, Lipshultz SE: Radiation. In Cardiology. Edited by Crawford MH, Dimarco JP. London: Mosby International Ltd; 2001:15.1–15.8. This chapter provides a comprehensive review of radiation associated heart disease, including pathology, clinical presentation, screening, and treatment.Google Scholar
  19. 19.
    Aisenberg AC: Problems in Hodgkin’s disease management. Blood 1999, 93:761–779.PubMedGoogle Scholar
  20. 20.
    Totterman KJ, Pesonen E, Siltanen P: Radiation related chronic heart disease. Chest 1983, 83:875–878.PubMedGoogle Scholar
  21. 21.
    Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 1993, 11:1208–1215. An important study of late cardiac effects of mediastinal irradiation.PubMedGoogle Scholar
  22. 22.
    Billingham ME, Bristow MR, Glatstein E, et al.: Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1977, 1:17–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Pihkala J, Saarinen UM, Lundstrom U, et al.: Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 1996, 32:97–103.CrossRefGoogle Scholar
  24. 24.
    Stewart JR, Fajardo LF, Gillette SM, et al.: Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995, 31:1205–1211.PubMedCrossRefGoogle Scholar
  25. 25.
    Heart Failure Guideline Panel: Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. Clinical Practice Guideline No 11. Rockville, MD: US Department of Health and Human Services, Agency for Health Care Policy and Research; 1994: AHCPR Publication 94:6012.Google Scholar
  26. 26.
    Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995, 92:2764–2784.Google Scholar
  27. 27.
    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.Google Scholar
  28. 28.
    Hensley ML, Schucter LM, Lindley C, et al.: American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999, 17:3333–3355.PubMedGoogle Scholar
  29. 29.
    Lipshultz SE: Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 1996, 14:328–331.PubMedGoogle Scholar
  30. 30.
    Lipshultz SE, Rifai N, Sallan SE, et al.: Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997, 96:2641–2648.PubMedGoogle Scholar
  31. 31.
    Herman EH, Zhang J, Lipshultz SE, et al.: Correlation between serum levels of cardiac troponin-T and the severity of chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999, 17:2237–2243.PubMedGoogle Scholar
  32. 32.
    Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Eng J Med 1992, 327:669–677.CrossRefGoogle Scholar
  33. 33.
    MICROMEDEX Healthcare Series, vol 109 [online database]. URL: http://mdx.com. Accessed June 27, 2001.Google Scholar
  34. 34.
    Drug Topics Red Book. Montvale, NJ: Medical Economics Co; 2001.Google Scholar
  35. 35.
    Noori A, Lindenfeld J, Wolfel E, et al.: Beta-blockade in adriamycin-induced cardiomyopathy. J Cardiac Fail 2000, 6:115–119.Google Scholar
  36. 36.
    Dillon TA, Sullivan M, Schatzlein MH, et al.: Cardiac transplantation in patients with preexisting malignancies. Transplantation 1991, 52:82–85.PubMedCrossRefGoogle Scholar
  37. 37.
    Stevenson LW, Warner SL, Steimle AE, et al.: The impending crisis awaiting cardiac transplantation. Modeling a solution based on selection. Circulation 1994, 89:450–457.PubMedGoogle Scholar
  38. 38.
    Li T, Singal PK: Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 2000, 102:2105–2110.PubMedGoogle Scholar
  39. 39.
    Cascinu S, Cordella L, Del Ferro E, et al.: Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995, 13:26–32.PubMedGoogle Scholar
  40. 40.
    De Maria D, Falchi AM, Venturino P: Adjuvant radiotherapy of the pelvis with or without reduced glutathione: a randomized trial of in patients operated on for endometrial cancer. Tumori 1992, 78:374–376.PubMedGoogle Scholar
  41. 41.
    Jain KK, Casper ES, Geller NL, et al.: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985, 3:818–826.PubMedGoogle Scholar
  42. 42.
    Cottin Y, Touzery C, Dalloz F, et al.: Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol 1998, 21:665–670.PubMedCrossRefGoogle Scholar
  43. 43.
    Anderlini P, Benjamin RS, Wong FC, et al.: Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995, 13:2827–2834.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Valeriano C. SimbreII
    • 1
  • M. Jacob Adams
    • 1
  • Sampada S. Deshpande
    • 1
  • Sarah A. Duffy
    • 1
  • Tracie L. Miller
    • 1
  • Steven E. Lipshultz
    • 1
  1. 1.Divisions of Cardiology and Gastroenterology/Nutrition, Department of Pediatrics, and Department of Community and Preventive MedicineUniversity of Rochester School of Medicine and DentistryRochesterUSA

Personalised recommendations